递送介导的外泌体疗法在缺血再灌注损伤中的研究进展、作用机制及未来方向

Delivery-mediated exosomal therapeutics in ischemia-reperfusion injury: advances, mechanisms, and future directions.

作者信息

Ding Shengzhe, Kim Yu-Jin, Huang Kai-Yu, Um Daniel, Jung Youngmee, Kong Hyunjoon

机构信息

Chemical & Biomolecular Engineering, University of Illinois, Urbana, IL, 61801, USA.

Center for Biomaterials, Korea Institute of Science and Technology, Seoul, 02792, Republic of Korea.

出版信息

Nano Converg. 2024 Apr 30;11(1):18. doi: 10.1186/s40580-024-00423-8.

Abstract

Ischemia-reperfusion injury (IRI) poses significant challenges across various organ systems, including the heart, brain, and kidneys. Exosomes have shown great potentials and applications in mitigating IRI-induced cell and tissue damage through modulating inflammatory responses, enhancing angiogenesis, and promoting tissue repair. Despite these advances, a more systematic understanding of exosomes from different sources and their biotransport is critical for optimizing therapeutic efficacy and accelerating the clinical adoption of exosomes for IRI therapies. Therefore, this review article overviews the administration routes of exosomes from different sources, such as mesenchymal stem cells and other somatic cells, in the context of IRI treatment. Furthermore, this article covers how the delivered exosomes modulate molecular pathways of recipient cells, aiding in the prevention of cell death and the promotions of regeneration in IRI models. In the end, this article discusses the ongoing research efforts and propose future research directions of exosome-based therapies.

摘要

缺血再灌注损伤(IRI)在包括心脏、大脑和肾脏在内的各种器官系统中都带来了重大挑战。外泌体已显示出通过调节炎症反应、增强血管生成和促进组织修复来减轻IRI诱导的细胞和组织损伤的巨大潜力和应用前景。尽管取得了这些进展,但更系统地了解不同来源的外泌体及其生物转运对于优化治疗效果和加速外泌体在IRI治疗中的临床应用至关重要。因此,本文综述了在IRI治疗背景下,来自间充质干细胞和其他体细胞等不同来源的外泌体的给药途径。此外,本文还阐述了递送的外泌体如何调节受体细胞的分子途径,有助于预防细胞死亡并促进IRI模型中的再生。最后,本文讨论了正在进行的研究工作,并提出了基于外泌体疗法的未来研究方向。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53ec/11061094/e3dc1baba43a/40580_2024_423_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索